Binding Free Energy Calculations of Adenosine Deaminase Inhibitor and the Effect of Methyl Substitution in Inhibitors

The binding affinity of an inhibitor is often improved ten times or more by introducing a simple substituent, such as a methyl group or a chlorine atom. We have investigated this phenomenon in the case of adenosine deaminase (ADA) inhibitors using molecular dynamics (MD) simulations and binding free energy calculations, by the linear interaction energy (LIE) method. For MD simulations, the coordination bond parameters and partial charges of atoms around the zinc ion in ADA have been determined by referring to ab initio MO calculations. The calculated binding free energies for seven inhibitors agreed well with the experimental ones, with a maximum error of 1.2 kcal/mol. The effect of methyl substitution in inhibitor molecules was examined on the basis of MD trajectories. It is suggested that the increase in binding affinity is caused by both van der Waals stabilizations by amino acid residues in contact with the introduced methyl group and through favored overall interactions with surrounding residues in the binding pocket.

[1]  Kenneth M. Merz,et al.  Force Field Design for Metalloproteins , 1991 .

[2]  P A Kollman,et al.  What determines the van der Waals coefficient β in the LIE (linear interaction energy) method to estimate binding free energies using molecular dynamics simulations? , 1999, Proteins.

[3]  Angelo Vedani,et al.  A new force field for modeling metalloproteins , 1990 .

[4]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[5]  John Marelius,et al.  Calculation of Ligand Binding Free Energies from Molecular Dynamics Simulations , 1998 .

[6]  H. Yuksel,et al.  Serum and synovial fluid adenosine deaminase activity in patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. , 1988, Annals of the rheumatic diseases.

[7]  B. H. Davis,et al.  Adenosine deaminase activity in lymphoid subpopulations and leukemias. , 1981, Cancer research.

[8]  J. Shryock,et al.  Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. , 1997, The American journal of cardiology.

[9]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[10]  J. Aqvist,et al.  A new method for predicting binding affinity in computer-aided drug design. , 1994, Protein engineering.

[11]  Takayoshi Kinoshita,et al.  Structure-based design, synthesis, and structure-activity relationship studies of novel non-nucleoside adenosine deaminase inhibitors. , 2004, Journal of medicinal chemistry.

[12]  T. Kinoshita,et al.  Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors. , 2004, Journal of medicinal chemistry.

[13]  M. Weyden,et al.  Adenosine deaminase deficiency and severe combined immunodeficiency disease. , 1977, Life sciences.

[14]  Olivier Michielin,et al.  Protein-ligand binding free energy estimation using molecular mechanics and continuum electrostatics. Application to HIV-1 protease inhibitors , 2003, J. Comput. Aided Mol. Des..

[15]  W. L. Jorgensen,et al.  Binding affinities for sulfonamide inhibitors with human thrombin using Monte Carlo simulations with a linear response method. , 1997, Journal of medicinal chemistry.

[16]  R. Ornstein,et al.  Binding free energy calculations for P450cam-substrate complexes. , 1996, Protein engineering.

[17]  Takayoshi Kinoshita,et al.  Structure-based de novo design of non-nucleoside adenosine deaminase inhibitors. , 2003, Bioorganic & medicinal chemistry letters.

[18]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[19]  K. Merz,et al.  Insights into the Structure and Dynamics of the Dinuclear Zinc β-Lactamase Site from Bacteroides fragilis† , 2002 .

[20]  Ruhong Zhou,et al.  New Linear Interaction Method for Binding Affinity Calculations Using a Continuum Solvent Model , 2001 .

[21]  J. Pearson,et al.  Cardiovascular purinoceptors. , 1990, Physiological reviews.

[22]  Xiaojie Xu,et al.  Predictions of Binding of a Diverse Set of Ligands to Gelatinase-A by a Combination of Molecular Dynamics and Continuum Solvent Models , 2002 .

[23]  P. Kollman,et al.  Atomic charges derived from semiempirical methods , 1990 .

[24]  W. Nauta,et al.  The effects of alkyl substitution in drugs-I. Substituted dimethylaminoethyl benzhydryl ethers. , 1960, Journal of medicinal and pharmaceutical chemistry.

[25]  Jon Read,et al.  Structure-based design of protein tyrosine phosphatase-1B inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[26]  K M Merz,et al.  Molecular dynamics simulations of the mononuclear zinc-beta-lactamase from Bacillus cereus. , 2001, Journal of the American Chemical Society.

[27]  T. Hansson,et al.  Estimation of binding free energies for HIV proteinase inhibitors by molecular dynamics simulations. , 1995, Protein engineering.

[28]  Kenneth M. Merz,et al.  CO2 binding to human carbonic anhydrase II , 1991 .

[29]  A. Tropsha,et al.  Beware of q 2 , 2002 .

[30]  Takayoshi Kinoshita,et al.  A highly potent non-nucleoside adenosine deaminase inhibitor: efficient drug discovery by intentional lead hybridization. , 2004 .

[31]  P. Kollman,et al.  How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? , 2000 .

[32]  M Karplus,et al.  Zinc binding in proteins and solution: A simple but accurate nonbonded representation , 1995, Proteins.

[33]  Dimas Suárez,et al.  Molecular dynamics simulations of the dinuclear zinc‐β‐lactamase from Bacteroides fragilis complexed with imipenem , 2002, J. Comput. Chem..

[34]  R. Guieu,et al.  Adenosine and the nervous system: pharmacological data and therapeutic perspectives. , 1998, General pharmacology.

[35]  A. Gerbes,et al.  [Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage]. , 2002, Zeitschrift fur Gastroenterologie.

[36]  M L Lamb,et al.  Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method. , 1998, Journal of medicinal chemistry.

[37]  Sherry L. Mowbray,et al.  Sugar Recognition by a Glucose/Galactose Receptor , 1995, The Journal of Biological Chemistry.

[38]  M L Lamb,et al.  Estimation of the binding affinities of FKBP12 inhibitors using a linear response method. , 1999, Bioorganic & medicinal chemistry.

[39]  C. Lluis,et al.  Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles. , 1997, Journal of immunology.

[40]  F A Quiocho,et al.  A pre-transition-state mimic of an enzyme: X-ray structure of adenosine deaminase with bound 1-deazaadenosine and zinc-activated water. , 1993, Biochemistry.

[41]  Kenneth M. Merz,et al.  Solvent Dynamics and Mechanism of Proton Transfer in Human Carbonic Anhydrase II , 1999 .

[42]  J. Åqvist,et al.  Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities. , 1997, Journal of medicinal chemistry.

[43]  G Burnstock,et al.  Receptors for purines and pyrimidines. , 1998, Pharmacological reviews.

[44]  中町 祐司.  Specific increase in enzymatic activity of adenosine deaminase 1 in rheumatoid synovial fibroblasts , 2003 .

[45]  M. Alexis,et al.  The estrogen receptor and polyphenols: molecular simulation studies of their interactions, a review , 2006 .

[46]  K Nadassy,et al.  Analysis of zinc binding sites in protein crystal structures , 1998, Protein science : a publication of the Protein Society.